About This Study
The goal of this study is to test a new treatment for a type of breast cancer called high-risk early triple-negative breast cancer. We want to see if using the drugs sacituzumab govitecan and pembrolizumab together can treat cancer that is still there after surgery and keep it from coming back. The researchers will compare this to using pembrolizumab alone or with another drug called capecitabine.
Volunteers must have had triple-negative breast cancer that is still in the breast or lymph nodes after chemotherapy and surgery. The study team will provide more information.
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- After Study Follow-Up Activities
- Review of Medical History
- Physical Examinations
- Phone Calls and/or Emails
- Study Visits and Consultations
- Surveys/Questionnaires
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100 years old
- All Genders
Language
- This study enrolls English speakers only
Additional Study Information
- No compensation provided
- Reimbursement offered
Study Locations
- Greater Winston-Salem, NC